Would you want to know if you or your children had risk of hereditary cancer, a genetic risk for cardiovascular disease or carried the gene associated with developing Alzheimer's disease - even if they were risks that wouldn't be relevant for possibly decades or didn't have a cure?

 Researchers used data from a cross-sectional online survey of a nationally-representative sample of the U.S. population that was conducted as part of the C.S. Mott Children's Hospital National Poll on Children's Health and found that 80 percent showed the same interest in genome sequencing for themselves as they did for their kids and 59 percent wanted to know if they had disease risks.
Using a small amount of blood or saliva, whole genome sequencing makes that possible. 

Mothers as a group and parents whose youngest children had more than two health conditions had significantly more interest in predictive genetic testing for themselves and their youngest children while those with conservative political ideologies had considerably less interest. 

"As genome sequencing becomes faster and cheaper, we expect the technology to become used more frequently in clinics and the private market. We wanted to know what kind of factors influenced patient demand for this test, especially among parents," says senior author Beth Tarini, M.D., M.S., assistant professor of pediatrics at University of Michigan's C.S. Mott Children's Hospital and researcher at the Child Health Evaluation and Research (CHEAR) Unit. "Particularly fascinating was that parents' interest for having predictive genetic testing done for themselves reflected their interest in testing their children too - it appears to be a global decision for the family." 

Nearly 62 percent of parents said they'd be interested in the complete DNA read for themselves and 58 percent of parents were interested for their children.

Planning to have a child in the next five years was also significantly associated with greater interest in genome sequencing among adults overall but not significant among current parents. Authors speculate this could be because parents who have already had a healthy child may have "minds at ease concerning their own genetic makeup" compared to nonparents.

Whole genome sequencing is a laboratory process that examines a person's DNA makeup in order to provide information about the risk for developing diseases in the future, as well as to diagnose active symptoms or diseases. Currently, the technology is most commonly used to find a medical cause for patients who already have symptoms for an undiagnosed health condition.

While sequencing could reveal risk of a handful of rare and preventable diseases, authors note there is concern for how accurately the information would be interpreted and how useful it will actually be for patients.

"It's a test that gives you a lot of data but the devil is in the details," Tarini says. "First, interpreting the data is challenging because we are not sure what all of the data means. Second, even if you can interpret the data then you may not know what to do with the interpretation. Perhaps you learn you have a slightly higher risk of getting prostate cancer or diabetes - neither of which is for certain or in the near future. Now what?"

Ethical questions abound too - privacy for example. Parents may be interested in testing their children and learn risks of diseases that wouldn't affect them until they were adults, such as breast cancer. These decisions could be deferred until the child is old enough to participate in them.

"We want our patients to be active participants in their health; however, the value of genome sequencing in helping individuals understand their disease risks is still controversial, especially for children," says lead author Daniel Dodson, a University of Michigan medical student.

"We hope our data will help clinicians both educate their patients regarding this technology, and partner with their patients in making well-informed health decisions."

Funding: Tarini was supported by the Clinical Sciences Scholars Program at the University of Michigan and a K23 Mentored Patient-Oriented Research Career Development Award from the National Institute for Child Health and Human Development (K23HD057994)

Citation: "Parent and Public Interest in Whole-Genome Sequencing," Public Health Genomics.  Additional Authors: Aaron Goldenberg, of the Department of Bioethics, Case Western Reserve University in Cleveland; Matthew Davis, M.D., M.A.P.P., professor of pediatrics and internal medicine at the U-M Medical School, professor of public policy at the U-M Gerald R. Ford School of Public Policy, director of the C.S. Mott Children's Hospital National Poll on Children's Health, professor of health management and policy at the School of Public Health and of CHEAR; and Dianne Singer, M.P.H., of CHEAR and NPCH. Davis and Tarini are also members of the U-M Institute for Healthcare Policy and Innovation.